Dasatinib, an inhibitor of Src and Abl kinases, was shown to disrupt key cytoskeletal and cytoskeletal-associated (cytoskeletome) proteins in dexamethasone-treated human trabecular meshwork (HTM) cells, with potential implications for IOP regulation in glaucoma [106]. Here, SRC is linked to glaucoma.